An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment

Sustained in vivo depletion of splenic langerin+ CD8α+ dendritic cells is well-tolerated by lang-DTREGFP mice

(2014) Kelly A. Prendergast et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome

(2013) Victoria T. Potter et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

(2013) F. Mussai et al.   BLOOD

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

(2013) R. B. Walter et al.   BLOOD

Immunotherapeutic strategies for relapse control in acute myeloid leukemia

(2013) Anna Martner et al.   BLOOD REVIEWS

Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy

(2013) R. Weinkove et al.   HAEMATOLOGICA

Critical stoichiometric ratio of CD4+ CD25+ FoxP3+regulatory T cells and CD4+ CD25−responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia

(2013) Kaushik Bhattacharya et al.   IMMUNOLOGY

Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

(2013) Cornelia Eckert et al.   JOURNAL OF CLINICAL ONCOLOGY

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

(2013) Lisa Christiansson et al.   PLoS One

Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: To Whom, When, and How

(2013) John Magenau et al.   Current Oncology Reports

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma

(2012) S. R. Mattarollo et al.   BLOOD

Race and ethnicity in decisions about unrelated hematopoietic stem cell donation

(2012) G. E. Switzer et al.   BLOOD

Economics of hematopoietic cell transplantation

(2012) N. Khera et al.   BLOOD

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

(2012) J. Richter et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia

(2012) J. Greiner et al.   BLOOD

Impairment of CD4+cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma

(2012) Junliang Fu et al.   HEPATOLOGY

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

(2012) Dennis Lindau et al.   IMMUNOLOGY

Transient Foxp3+ regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells

(2012) Stephen R Mattarollo et al.   IMMUNOLOGY AND CELL BIOLOGY

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

(2011) C. Ustun et al.   BLOOD

Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia

(2011) Evelien L. J. Smits et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients

(2011) Sebastian Ochsenreither et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Administration of  -galactosylceramide impairs the survival of dendritic cell subpopulations in vivo

(2011) H. M. A. Simkins et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Exploiting the Role of Endogenous Lymphoid-Resident Dendritic Cells in the Priming of NKT Cells and CD8+ T Cells to Dendritic Cell-Based Vaccines

(2011) Troels R. Petersen et al.   PLoS One

A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors

(2010) M. J. Goldstein et al.   BLOOD

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

(2010) C. G. Kanakry et al.   BLOOD

How I treat acute myeloid leukemia

(2010) J. M. Rowe et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909

(2010) Jürgen Kuball et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells

(2010) A. Curti et al.   HAEMATOLOGICA

Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells

(2010) S. Nagaraj et al.   JOURNAL OF IMMUNOLOGY

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

(2010) V. F. Van Tendeloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

(2009) Q. Zhou et al.   BLOOD

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia

(2009) M. J. Szczepanski et al.   CLINICAL CANCER RESEARCH

In vivodepletion of CD4+FOXP3+Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcγRIII+phagocytes

(2009) Yulius Y. Setiady et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Novel Subset of CD8 + Dendritic Cells Localized in the Marginal Zone Is Responsible for Tolerance to Cell-Associated Antigens

(2009) C.-H. Qiu et al.   JOURNAL OF IMMUNOLOGY

Langerin+CD8 + Dendritic Cells Are Critical for Cross-Priming and IL-12 Production in Response to Systemic Antigens

(2009) K. J. Farrand et al.   JOURNAL OF IMMUNOLOGY

Antibody to Langerin/CD207 localizes large numbers of CD8 + dendritic cells to the marginal zone of mouse spleen

(2009) J. Idoyaga et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhancement of the anti-tumor efficacy of a GM-CSF–secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside

(2008) J LIN   EXPERIMENTAL HEMATOLOGY

Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster (ALL-BFM) Trials

(2008) Andishe Attarbaschi et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE